IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
Si, TianMei1; Tan, QingRong2; Zhang, KeRang3; Wang, Yang4; Rui, Qing4
关键词paliperidone first-episode psychosis Personal and Social Performance score
刊名NEUROPSYCHIATRIC DISEASE AND TREATMENT
2015
DOI10.2147/NDT.S70694
11页:87-95
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology ; Psychiatry
研究领域[WOS]Neurosciences & Neurology ; Psychiatry
关键词[WOS]1ST-EPISODE SCHIZOPHRENIA ; POOLED DATA ; EFFICACY ; TABLETS ; RISPERIDONE ; 6-WEEK ; SAFETY ; TRIAL ; ER
英文摘要

Background: Antipsychotic medications facilitate the improvement of psychotic symptoms in patients with first-episode psychosis. Paliperidone extended-release (pali-ER), an atypical antipsychotic, was assessed for efficacy and safety in Chinese patients with first-episode psychosis.

Methods: In this 8-week, open-label, single-arm, multicenter study, patients with first-episode psychosis (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Positive and Negative Syndrome Scale (PANSS) total score >= 70 were treated with flexible-dose pali-ER tablets (3-12 mg/day). The primary efficacy endpoint was the percentage of patients with an increase of >= 8 points in Personal and Social Performance (PSP) score from baseline to day 56 (8 weeks). Secondary endpoints included reduction in PANSS total score, improvement in Clinical Global Impression-Severity score, PSP score, Subjective Well-being under Neuroleptics Scale score, and relationship between duration of untreated psychosis and PANSS or PSP. Incidences of treatment-emergent adverse events were used to evaluate safety.

Results: Overall, 283 of 294 patients (96%) achieved a >= 8-point increase in PSP (primary endpoint, analysis set). For the secondary efficacy endpoints, 284/306 patients (93%) had a >= 30% reduction in PANSS total score; 266/306 patients (87%) achieved a <= 3 Clinical Global Impression-Severity scale score, and 218/294 patients (74%) had a PSP score >= 71. The Subjective Well-being under Neuroleptics Scale score was improved from a baseline mean of 72.7 to 94.7 at endpoint. There was a negative correlation between duration of untreated psychosis and posttreatment PSP score and a positive correlation with posttreatment PANSS total score. The most common treatment-emergent adverse events were extrapyramidal symptoms (12%), and agitation, somnolence, and xerostomia (4% each).

Conclusion: An 8-week, flexible-dose (3-12 mg/day) treatment with pali-ER resulted in significant improvements in psychotic symptoms and was generally tolerable.

语种英语
WOS记录号WOS:000347386000001
项目编号20112X09302-004 ; 81171284
资助机构Xian-Janssen Pharmaceutical Ltd ; National Science and Technology Major Projects for "Major New Psychiatric Drugs Innovation and Development" ; National Natural Science Foundation of China
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59232
专题北京大学精神卫生研究所
作者单位1.Shanxi Med Univ, Hosp 1, Taiyuan, Shanxi, Peoples R China
2.Janssen Res & Dev, Beijing, Peoples R China
3.Peking Univ, Inst Mental Hlth, Key Lab Mental Hlth, Minist Hlth, Beijing 100191, Peoples R China
4.Fourth Mil Med Univ, Hosp 1, Xian 710032, Peoples R China
推荐引用方式
GB/T 7714
Si, TianMei,Tan, QingRong,Zhang, KeRang,et al. An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis[J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT,2015,11:87-95.
APA Si, TianMei,Tan, QingRong,Zhang, KeRang,Wang, Yang,&Rui, Qing.(2015).An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis.NEUROPSYCHIATRIC DISEASE AND TREATMENT,11,87-95.
MLA Si, TianMei,et al."An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis".NEUROPSYCHIATRIC DISEASE AND TREATMENT 11(2015):87-95.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Si, TianMei]的文章
[Tan, QingRong]的文章
[Zhang, KeRang]的文章
百度学术
百度学术中相似的文章
[Si, TianMei]的文章
[Tan, QingRong]的文章
[Zhang, KeRang]的文章
必应学术
必应学术中相似的文章
[Si, TianMei]的文章
[Tan, QingRong]的文章
[Zhang, KeRang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。